Enliven Therapeutics, Inc. (ELVN)
NASDAQ: ELVN · Real-Time Price · USD
22.47
-0.40 (-1.75%)
Dec 20, 2024, 4:00 PM EST - Market closed

Enliven Therapeutics Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020
Period Ending
Sep '24 Dec '23 Dec '22 Dec '21 Dec '20
Cash & Equivalents
100.62100.1475.54110.02130.37
Short-Term Investments
191.21153.01---
Cash & Short-Term Investments
291.83253.1575.54110.02130.37
Cash Growth
10.76%235.14%-31.35%-15.60%-
Prepaid Expenses
5.112.952.220.650.06
Restricted Cash
0.050.05--0.05
Other Current Assets
-10--0.1
Total Current Assets
297266.1577.75110.67130.59
Property, Plant & Equipment
0.631.061.520.950.42
Long-Term Deferred Charges
0.560.563.981.65-
Other Long-Term Assets
7.244.090.050.05-
Total Assets
305.43271.8783.3113.33131
Accounts Payable
1.020.533.442.520.81
Accrued Expenses
15.7114.664.322.840.43
Current Portion of Leases
0.090.340.320.160.11
Other Current Liabilities
0.2210.361.640.230.14
Total Current Liabilities
17.0325.899.725.751.48
Long-Term Leases
--0.28--
Other Long-Term Liabilities
-0.070.380.710.08
Total Liabilities
17.0325.9610.376.471.56
Common Stock
0.050.04000
Additional Paid-In Capital
508.41400.176.042.310.16
Retained Earnings
-220.29-154.45-82.86-45.2-20.46
Comprehensive Income & Other
0.240.14---
Total Common Equity
288.4245.91-76.83-42.89-20.3
Shareholders' Equity
288.4245.9172.92106.86129.45
Total Liabilities & Equity
305.43271.8783.3113.33131
Total Debt
0.090.340.60.160.11
Net Cash (Debt)
291.75252.8174.94109.87130.26
Net Cash Growth
10.87%237.37%-31.79%-15.66%-
Net Cash Per Share
6.507.1123.9914.0626.12
Filing Date Shares Outstanding
48.8641.3512.111.644.99
Total Common Shares Outstanding
47.2541.2912.111.644.99
Working Capital
279.97240.2668.04104.92129.11
Book Value Per Share
6.105.96-6.35-3.68-4.07
Tangible Book Value
288.4245.91-76.83-42.89-20.3
Tangible Book Value Per Share
6.105.96-6.35-3.68-4.07
Machinery
1.461.411.260.650.46
Source: S&P Capital IQ. Standard template. Financial Sources.